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Key messages
What is already known about this subject?
 ► Patients with rheumatoid arthritis (ra) have an in-
creased risk of infections, but the prognosis of in-
fections is unclear.
What does this study add?
 ► in this large population- based cohort study, the over-
all mortality after hospitalised pneumonia among ra 
patients was not increased compared with non- ra 
patients.
 ► however, we identified a higher mortality among pa-
tient with high disease activity prior to pneumonia 
hospitalisation.
 ► reassuringly, treatment with biologics and conven-
tional synthetic disease- modifying antirheumatic 
drugs, either as a monotherapy or in combination, 
did not predict increased pneumonia mortality.
How might this impact on clinical practice?
 ► high ra disease activity rather than ra medication is 
associated with poorer prognosis after hospitalised 
pneumonia.
AbstrAct
Objective Patients with rheumatoid arthritis (ra) 
experience an increased risk of infections, but the 
prognosis of infections is unclear. We examined if patients 
with ra have worse outcomes from pneumonia than non- 
ra individuals.
Methods in a population- based cohort study, we 
computed 90- day mortality rates and crude and adjusted 
hrs comparing pneumonia patients with and without ra. 
among patients with ra, we evaluated prognostic effects 
of ra medications including prednisolone and disease 
activity as assessed by c reactive protein (crP) or platelet 
levels measured 30–180 days before admission to avoid 
any influence from the subsequent infection.
Results among 52 577 patients hospitalised for the first 
time with pneumonia, 1220 (2.3%) had ra. The 90- day 
mortality was 19.9% for patients with ra and 18.9% for 
non- ra patients (adjusted 90- day hr of 1.05 (95% ci 
0.92 to 1.19)). compared with crP levels <8 mg/l, crP 
levels ≥20 mg/l predicted increased mortality in patients 
with ra with adjusted 90- day hrs of 4.98 (95% ci 2.19 to 
11.36). compared with methotrexate monotherapy, both 
prednisolone (hr 1.43 (95% ci 0.91 to 2.22)) and no ra 
therapy (hr 1.35 (95% ci 0.85 to 2.14)) tended to increase 
90- day mortality. compared with patients who used 
prednisolone and had low crP levels, high crP predicted 
increased mortality both in patients who used prednisolone 
(hr 3.09, 95% ci 1.25 to 7.65) and those who did not (hr 
2.35, 95% ci 0.94 to 5.87).
Conclusions Overall, ra does not increase mortality 
following hospitalisation for pneumonia. however, high 
ra disease activity prior to admission predicts increased 
pneumonia mortality in patients regardless of prednisolone 
use.
InTROduCTIOn and aIMs
Patients with rheumatoid arthritis (RA) 
have increased mortality compared with the 
general population, with age- standardised 
mortality ratios of 1.2–2.6.1–6 Major causes 
of death include cardiovascular disease, 
lung fibrosis and infections, particularly 
pneumonia.4 5 7 8 Thomas et al found a stand-
ardised mortality ratio for respiratory infec-
tions among patients with RA compared with 
the general population of 1.92 (1.72–2.15) 
for women and 2.42 (2.28–2.57) for men.2 
Several studies have shown an increased risk 
of other serious infections requiring hospital-
isation in patients with RA.9–11
It remains unclear if the increased mortality 
due to infections in RA can be explained 
solely by the increased risk of acquiring 
infections or if patients with RA have worse 
infection outcomes as well. RA may influ-
ence the outcomes of pneumonia and other 
infections due to the RA disease activity per 
se, the related comorbidities or the use of 
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immunosuppressive therapy. Patients with RA with high 
disease activity are more likely to undergo intensive 
treatment with prednisolone, combination therapy with 
conventional synthetic disease- modifying antirheumatic 
drugs (csDMARDs) and biologics. This leads to concerns 
about the risk of severe infections associated with inten-
sive treatment with corticosteroids and biologics.11 On the 
other hand, if patients with untreated RA disease activity 
have similar or even worse infection outcomes as patients 
receiving immunosuppressive drugs, this would support 
the strategy of intensive treatment even in patients with 
RA prone to infections.
The purpose of the present study was to examine 
whether RA is associated with increased mortality in 
patients who are hospitalised with pneumonia and to 
evaluate whether RA disease activity with or without 
treatment with csDMARDs, biologics or prednisolone 
prior to admission influences the prognosis. We hypoth-
esised that patients with RA have worse outcomes from 
pneumonia than non- RA individuals and that both high 
disease activity and the use of prednisolone worsen the 
prognosis.
PaTIenTs and MeTHOds
setting and study population
We conducted a population- based cohort study in the 
northern and central regions of Jutland, with approx-
imately 1.8 million inhabitants. Data were obtained 
from medical registries, and since all Danish citizens are 
assigned a unique personal identification number (CPR) 
at birth, the data from different registries can be cross- 
linked at the individual level.12 The Danish National 
Patient Register (DNPR) was used to identify patients 
with pneumonia. Please see the online supplementary 
file for a thorough description of the DNPR. We included 
all adult patients (≥16 years) with a first- time primary 
hospital discharge diagnosis of pneumonia (ICD10: 
J12.x- J18.x, A481x, A709.x) between January 1997 and 
31 December 2011; thus, patients with a prior discharge 
diagnosis of pneumonia were excluded. The validity of a 
pneumonia diagnosis in this register has previously been 
evaluated and found to be high, with a positive predictive 
value (PPV) of 90% (95% CI 82% to 95%).13
data on Ra and validation of the diagnosis
Data on RA were obtained from the DNPR (ICD-8 codes: 
712 excluding 712.09 and 712.49, ICD-10 codes: M05 and 
M06). We reviewed medical records of 190 patients with 
RA diagnosis and found a PPV of 88% (95% CI 83% to 
93%) for true RA; see online supplementary file for more 
details.
data on medication
Data on RA treatment were assessed from three health-
care registries: The DNPR, the Aarhus University 
Prescription Database14 and DANBIO.15 Please see the 
online supplementary file for a thorough description of 
these databases.
In the DNPR, treatment with csDMARDs and biologics 
were coded in relation to visits to hospital outpatient 
clinics. Most of the patients with RA were seen at least 
annually; therefore, we retrieved information on all the 
treatments registered within 12 months prior to pneu-
monia hospitalisation.
From the Aarhus University Prescription Database,14 
we obtained information on filled community pharmacy 
prescriptions for csDMARDs (see online supplemen-
tary file for all of the Anatomical Therapeutic Chemical 
Classification System codes) within 12 months before 
pneumonia hospitalisation and prescriptions for pred-
nisolone filled within 3 months before pneumonia hospi-
talisation. In addition, we obtained information on filled 
prescription for Non Steroidal Anti- Inflammatory Drugs 
(NSAIDs).
When a patient with RA is seen by a rheumatologist, 
a ‘visit’ is created in DANBIO. A visit consists of infor-
mation regarding the current functional status, disease 
activity, treatment, and Visual Analogue Scale scores of 
pain, fatigue and of the patient and physician’s global 
assessment. For the subgroup of pneumonia patients who 
were registered in the DANBIO database, we retrieved 
information from the last visit within 0–180 days before 
the pneumonia hospitalisation. If the patient had more 
than one registration in DANBIO within the 180 days, the 
later instance was used.
Since some RA medications are dispensed at the 
hospital and some are written as prescriptions, we took 
this into account when defining RA treatment. A patient 
was defined as being treated with biologics if there was 
either a registration in DANBIO or the DNPR with 
this information. Since methotrexate (MTX) can be 
administered either orally (prescription) or subcutane-
ously (dispensed at the hospital), treatment with MTX 
was defined as a registration in either the DNPR or the 
Aarhus University Prescription Database. Treatment with 
leflunomide was similarly defined as a registration in 
either the DNPR or the Aarhus University Prescription 
Database. However, all the other csDMARDs and pred-
nisolone treatments were defined as registrations in the 
Aarhus University Prescription Database.
We categorised all of the patients with RA according 
to the type of RA medication prior to admission into the 
following groups: (1) any prednisolone treatment, (2) 
any biological treatment, (3) MTX monotherapy, (4) 
other csDMARDs monotherapy, (5) csDMARDs combina-
tion therapy and (6) no RA medication. If a patient was 
treated with therapies from several groups, a hierarchical 
structure was used: if a patient had received a prescrip-
tion for prednisolone in the period 0–3 months before 
pneumonia diagnosis, the patients was categorised in the 
‘any prednisolone group’ irrespective of any other RA 
medication. Among the remaining patients, those who 
received any biologics (0–12 months) before the pneu-
monia diagnoses were categorised in the ‘any biologic 
group’. Patients without prednisolone and biologics 
were categorised as either ‘MTX monotherapy’, ‘other 
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csDMARD monotherapy’, ‘csDMARDs combination 
therapy’ or ‘no RA medication’. An overview is presented 
in online supplementary figure 1. We did not have infor-
mation on doses for any DMARDs or prednisolone.
For all of the pneumonia patients, we also acquired 
data on filled prescriptions for antibiotics at any commu-
nity pharmacy 0–30 days prior to their hospitalisation 
for pneumonia from the Aarhus University Prescription 
Database (see the online supplementary file for codes).
data on disease activity
Previous studies have shown that elevated C reactive 
protein (CRP) levels and elevated platelet counts are 
valid markers of RA disease activity.16–19 Information on 
CRP and platelets was obtained from the clinical labora-
tory information system research database. Please see the 
online supplementary file for a thorough description of 
this database.
We obtained data on CRP and platelets measured 30–90 
days before pneumonia hospitalisation. In cases of more 
than one measurement made 30–90 days before hospi-
talisation, the most recent value was selected. Measure-
ments from 1 to 30 days before admission were omitted 
to avoid any influence from the subsequent infection.
In the subgroup of patients with a visit recorded in 
DANBIO 0–90 days prior to admission, we used informa-
tion on disease activity from the latest visit.
Comorbidity data
From the DNPR, we obtained information on previous 
alcoholism- related diagnoses and the 19 conditions 
included in the Charlson Comorbidity Index (excluding 
RA diagnoses) recorded within 10 years before the pneu-
monia hospitalisation. In a previous study, the coding in 
the DNPR for the 19 Charlson conditions was found to 
have an overall PPV of 98%.20 The index has been vali-
dated for the prediction of mortality following hospitali-
sation.21 22 We assessed the three comorbidity index levels 
according to the Charlson Comorbidity Index scores as 
follows: score of 0, low; score of 1–2, medium and score 
of 3+, high.
Pneumonia outcome
The primary outcome was death from any cause within 
30 and 90 days from the pneumonia hospitalisation. The 
date of eventual death was ascertained from the Danish 
Civil Registration System.12
statistical analysis
Pneumonia prognosis in patients with ra versus non-ra
Follow- up time was computed from the date of pneu-
monia admission until migration, death or 90 days after 
the admission date, whichever came first. Mortality after 
30 and 90 days was estimated for both patients with RA 
and non- RA. We used Cox regression to compute the 
crude and adjusted HRs for death within 30 and 90 days 
following hospital admission to compare patients with 
RA and non- RA, controlling for sex, age, level of comor-
bidities, alcoholism and use of antibiotics within 30 days 
before admission. We additionally stratified the analysis 
by calendar time for the pneumonia diagnosis (1997–
2001, 2002–2006 and 2007–2011) and for chronic lung 
disease.
Prognostic effect of ra disease activity
In pneumonia patients with RA, we compared 30- day 
and 90- day mortality according to CRP levels prior to 
admission (CRP <8 mg/L (reference), 8–19.9 mg/L, 
>20 mg/L) using Cox regression. Similar analyses were 
performed for platelet levels (<350×109/L (reference), 
350–400×109/L, >400×109/L). To examine if an associa-
tion between high RA disease activity and mortality could 
be explained by a higher prevalence of prednisolone use, 
we conducted disease activity analyses with and without 
adjustment for prednisolone prescriptions filled within 
3 months prior to admission, in addition to sex, age, 
level of comorbidity, alcoholism and prescribed antibi-
otics. In addition, we estimated the effect on mortality 
with numerical increases in CRP levels by 10 mg/L and 
increases in platelet counts by 20×109/L.
In patients with RA with a visit registered in DANBIO 
0–90 days prior to pneumonia admission, we compared 
the mortality between high and low disease activity (ie, 
those with a Disease Activity Score 28 joints (DAS28) 
>3.2 and those with a DAS28 <3.2) adjusting for sex, age 
and level of comorbidity.
Prognostic effect of prednisolone and other medications prior to 
admission in patients with ra
To evaluate the effect of RA therapy on pneumonia 
outcome, we categorised patients with RA according to 
type of RA medication prior to admission. We computed 
the crude HRs for mortality within 30 and 90 days of 
using MTX as a reference, since MTX was frequently used 
and is regarded as a cornerstone of RA treatment. We 
adjusted for sex, age, level of comorbidities, alcoholism 
and antibiotic use before admission.
interaction between prednisolone and disease activity
We examined the prognostic effect of prednisolone 
separately stratified by low or high CRP levels before 
the pneumonia admission. Next, we used patients with 
no prescriptions for prednisolone and low CRP levels 
as a reference and computed the HRs for mortality in 
patients with prescriptions for prednisolone and low CRP 
levels, patients without prescriptions for prednisolone 
and elevated CRP levels, and patients with prescriptions 
for prednisolone and elevated CRP levels.
Statistical analyses were performed using the Stata 
V.12.1 statistical software package (StataCorp). HRs are 
presented as point estimates with 95% CIs.
ResulTs
descriptive data
A total of 52 577 patients were hospitalised for pneumonia 
between 1997 and 2011. Among these, 1220 (2.3%) had a 
diagnosis of RA. Patients with RA were slightly older, were 
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Table 1 Characteristics of patients with and without 
rheumatoid arthritis (RA) who were hospitalised for 
pneumonia from 1997 to 2011 in northern Denmark
RA Non- RA
N 1220 (2.3%) 51 357 (97.7%)
Pneumonia 1997–2001 277 (1.8%) 15 011 (98.2%)
Pneumonia 2002–2006 411 (2.3%) 17 657 (97.7%)
Pneumonia 2007–2011 532 (2.8%) 18 674 (97.2%)
Age, median 74 (66–80) 72 (59–81)
  16–39 years 18 (1.5%) 4406 (8.6%)
  40–49 years 35 (2.9%) 3311 (6.5%)
  50–59 years 120 (9.8%) 5739 (11.2%)
  60–69 years 249 (20.4%) 8890 (17.3%)
  70–79 years 454 (37.2%) 13 176 (25.7%)
  80–89 years 306 (25.1%) 12 699 (24.7%)
  90–105 years 38 (3.1%) 3136 (6.1%)
Sex
  Women 801 (65.7%) 24 018 (46.8%)
  Men 419 (34.3%) 27 339 (53.2%)
Comorbidity
  Congestive heart failure 170 (13.9%) 5269 (10.3%)
  Peripheral vascular 
disease
118 (9.7%) 3811 (7.4%)
  Previous myocardial 
infarction
104 (8.5%) 3443 (6.7%)
  Chronic pulmonary 
disease
291 (23.9%) 10 431 (20.3%)
  Cerebrovascular 
disease
174 (14.3%) 6936 (13.5%)
  Haemiplegia 5 (0.4%) 335 (0.7%)
  Dementia 17 (1.4%) 1246 (2.4%)
  Connective tissue 
disease
109 (8.9%) 1425 (2.8%)
  Peptic ulcer disease 118 (9.7%) 3064 (6.0%)
  Diabetes 1 and 2 106 (8.7%) 4024 (7.8%)
  Diabetes with end 
organ damage
65 (5.3%) 2155 (4.2%)
  Moderate to severe 
renal disease
83 (6.8%) 1967 (3.8%)
  Any tumour 146 (12.0%) 6914 (13.5%)
  Leukaemia 13 (1.1%) 670 (1.3%)
  Lymphoma 21 (1.8%) 1160 (2.3%)
  Metastatic solid tumour 32 (2.6%) 1568 (3.1%)
  Mild liver disease 16 (1.3%) 757 (1.5%)
  Moderate- to- severe 
liver disease
4 (0.3%) 231 (0.5%)
  AIDS <3 70 (0.1%)
  Alcoholism- related 
disorders
17 (1.4%) 2411 (4.7%)
Continued
more often women and had higher comorbidity than 
non- RA patients. The proportion of patients receiving 
antibiotics prior to pneumonia admission did not differ 
by RA status, nor did the duration of the hospital stay 
(table 1). Prior to admission, 155 (12.7%) of the patients 
with RA had at least one registration in DANBIO. In 69 
patients, the last registration was within 90 days prior to 
admission.
Mortality in patients with Ra versus non-Ra
We found a 90- day mortality in pneumonia patients with 
RA of 19.9% compared with 18.9% in non- RA pneu-
monia patients. Corresponding crude 90- day HR was 1.07 
(95% CI 0.94 to 1.21), and adjusted HR was 1.05 (95% CI 
0.92 to 1.19) (table 2).
Among patients with RA, the 90- day pneumonia 
mortality decreased from 22.0% in 1997–2001 to 
19.2% and 19.4% in 2002–2006 and 2007–2011, respec-
tively. A similar decrease was found among non- RA 
patients, suggesting an overall improved prognosis for 
pneumonia over time. When comparing the 30- day 
mortality of the patients with RA with the non- RA patients 
we found adjusted HRs of 1.15 (95% CI 0.84 to 1.57) in 
1997–2011, 1.03 (95% CI 0.78 to 1.35) in 2002–2006 and 
1.08 (95% CI 0.85 to 1.36) in 2007–2011. The stratified 
analyses of patients with and without lung disease are 
presented in table 2.
In the adjusted model for both 30- day and 90- day 
mortality, the potential confounders male gender, 
increasing age, comorbidity level and an alcohol- related 
diagnosis was associated with increased mortality after 
pneumonia. HR for 90- day mortality for these variables 
was 1.19 (1.14–1.24) if patients were male, 1.05 (1.05–
1.05) for an age increase by 1 year, 1.20 (1.19–1.21) for 
each increase in comorbidity level and 1.66 (1.51–1.83) 
if the patient had an alcohol related diagnosis. Prior use 
of antibiotics was not associated with change in mortality 
(HR 1.02 (0.98–1.07)). These HR estimates for 30- day 
mortality were almost identical. In addition, HR for 
these confounders were similar for patients with RA and 
non- RA.
Prognostic effect of disease activity in patients with Ra
CRP measurements within 30–90 days prior to admission 
were available for 704 (58%) patients with RA (table 3). 
In these patients, CRP levels were <8 mg/L in 15.1% of 
patients, 8–19.9 mg/L in 29.4% of patients and ≥20 mg/L 
in 55.5% of patients. The 30- day mortality in the group 
with low CRP levels (<8 mg/L) was 4.7% compared with 
6.8% and 17.9% in the groups with CRP levels ranging 
from 8 to 19.9 mg/L and CRP levels ≥20 mg/L, respec-
tively. Compared with the group with low CRP (<8 mg/L), 
we found crude 30- day HRs for mortality in the groups 
with CRP levels ranging from 8 to 19.9 mg/L and CRP 
levels ≥20 mg/L of 1.45 (95% CI 0.52 to 4.01) and 4.03 
(95% CI 1.63 to 9.99), respectively. When adjusted for 
prednisolone prescriptions filled within 3 months prior 
to admission, sex, age, level of comorbidity, alcoholism 
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RA Non- RA
Comorbidity Index (level of Charlson Index Score)
  Low (0) 391 (32.1%) 21 487 (41.8%)
  Medium (1–2) 543 (44.5%) 19 514 (38.0%)
  High (≥3) 286 (23.4%) 10 356 (20.2%)
Duration of hospital stay, 
median
6 (3–10) 6 (3–10)
Systemic antibiotic 
therapy before admission
445 (36.5%) 17 094 (33.3%)
Table 1 Continued
Table 2 Results of 30- day and 90- day all- cause mortality following hospitalisation for pneumonia in patients with and without 
rheumatoid arthritis (RA)
All pneumonia patients
Pneumonia patients with chronic 
lung disease
Pneumonia patients without 
chronic lung disease
RA Non- RA RA Non- RA RA Non- RA
N 1220 51 357 291 (23.9) 10 428 (20.3) 929 (76.1) 40 914 (79.7)
30- day 
mortality
165 (13.5%) 6521 (12.7%) 37 (12.7) 1335 (12.8) 128 (13.8) 5186 (12.7)
90- day 
mortality
243 (19.9%) 9679 (18.9%) 62 (21.3) 2118 (20.3) 181 (19.5) 7561 (18.5)
Crude 30- 
day HR
1.07 (0.92 to 1.25) 1.00 (ref) 1.00 (0.72 to 1.39) 1.00 (ref) 1.10 (0.92 to 1.30) 1.00 (ref)
Adjusted 
30- day HR*
1.06 (0.91 to 1.24) 1.00 (ref) 1.04 (0.75 to 1.46) 1.00 (ref) 1.07 (0.90 to 1.28) 1.00 (ref)
Crude 90- 
day HR
1.07 (0.94 to 1.21) 1.00 (ref) 1.06 (0.82 to 1.36) 1.00 (ref) 1.07 (0.92 to 1.23) 1.00 (ref)
Adjusted 
90- day HR*
1.05 (0.92 to 1.19) 1.00 (ref) 1.11 (0.86 to 1.42) 1.00 (ref) 1.03 (0.89 to 1.19) 1.00 (ref)
HRs with 95% CI were calculated using a Cox proportional hazards model.
*Adjusted for sex, age, level of comorbidity, alcoholism and antibiotic use before admission.
and prescribed antibiotics, the 90- day HRs were 1.42 
(95% CI 0.51 to 3.95) and 3.64 (95% CI 1.46 to 9.08), 
respectively. A numerical increase in CRP by 10 mg/L 
predicted an increase in mortality of 4% (95% CI 2% to 
6%). Analyses without adjustment for prednisolone are 
presented in table 3. They did not differ materially from 
the above mentioned analyses.
Data on platelet counts measured 30–90 days prior 
to admission were available for 681 (56%) patients 
with RA (table 4). Of these, 60.8% had platelet counts 
<350×109/L, 14.2% had platelet counts≥350 <400×109/L 
and 25% had platelet counts ≥400×109/L. Compared 
with patients with normal platelet counts (<350×109/L), 
the crude 90- day HR for mortality was 1.50 (95% CI: 0.94 
to 2.41) in patients with platelet counts ≥350<400×109/L 
and 1.84 (95% CI 1.28 to 2.66) in those with platelet 
counts ≥400×109/L. The corresponding adjusted 90- day 
HRs were 1.54 (95% CI 0.95 to 2.48) and 1.84 (95% CI 
1.27 to 2.66), respectively. An increase in platelet counts 
of 20×109/L predicted an increase in 90 day mortality of 
3% (1%–5%).
In the subgroup of patients who had a visit recorded 
in DANBIO within 90 days prior to admission, mortality 
was higher in patients with DAS28 >3.2 compared with 
patients with DAS28 ≤3.2 with a crude HR of 1.57 (95% 
CI 0.26 to 9.38) and an adjusted HR of 2.29 (95% CI 0.38 
to 13.86). However, only 57 patients were included in this 
analysis, and the precision of the estimates is therefore 
limited.
Prognostic effect of prednisolone and other medications prior 
to admission in patients with Ra
Compared with patients with RA treated with MTX 
monotherapy, patients with RA who did not receive any 
RA therapy had 30- day and 90- day mortality with HRs 
of 1.60 (95% CI 0.93 to 2.76) and 1.40 (95% CI 0.89 to 
2.23), respectively (table 4). When adjusted for sex, age, 
level of comorbidity, alcoholism and antibiotic use prior 
to admission, the 30- day and 90- day HRs for mortality 
were 1.49 (95% CI 0.86 to 2.57) and 1.35 (95% CI 0.85 
to 2.14), respectively. Patients with RA with at least one 
prescription for prednisolone within 3 months prior to 
hospitalisation had a more than 40% increased 90- day all- 
cause mortality compared with patients with RA treated 
with MTX. Treatment with biologics did not increase 
mortality (table 4). Of the 1220 patients with RA, 394 
did not receive RA therapy 0–12 months prior to admis-
sion. But 123 of these patients had previously (more 
than 1 year prior to the admission) been prescribed 
csDMARDS and 310 of them had been on NSAIDS. The 
number of patients presented in table 4 with a prescrip-
tion for NSAID was: MTX monotherapy: 2, any predniso-
lone: 7, any biologics: 0, other DMARDS as monotherapy: 
2, combination therapy (DMARDs): 1 and 19 in the ‘No 
RA medication’ medication group.
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Table 4 Results of all- cause mortality following hospitalisation for pneumonia: a subanalysis of patients with rheumatoid 
arthritis (RA) and their preadmission treatments for RA with patients receiving methotrexate as a reference
RA therapy
Mortality 
at 30 days 
n (%) HRs 30- day mortality
Mortality 
at 90 days 
n (%) HRs 90- day mortality
N Crude Adjusted* Crude Adjusted*
All 1220 165 (13.5) 243 (19.9)
Methotrexate 
monotherapy
143 16 (11.2) 1.0 (ref) 1.0 (ref) 23 (16.1) 1.0 (ref) 1.0 (ref)
Any 
prednisolone†
526 71 (13.5) 1.23 (0.72 to 
2.12)
1.16 (0.68 to 
2.01)
121 (23.0) 1.48 (0.95 to 
2.31)
1.43 (0.91 to 
2.22)
Any biologics 46 1 (2.2) 0.19 (0.02 to 
1.42)
0.35 (0.05 to 
2.66)
1 (2.2) 0.13 (0.02 to 
0.94)
0.21 (0.03 to 
1.56)
Other 
csDMARDS as 
monotherapy
63 8 (12.7) 1.17 (0.50 to 
2.73)
1.24 (0.53 to 
2.92)
10 (15.9) 1.01 (0.48 to 
2.12)
1.09 (0.52 to 
2.29)
Combination 
therapy 
(csDMARDs)
48 1 (2.0) 0.18 (0.02 to 
1.34)
0.27 (0.36 to 
2.06)
3 (6.2) 0.37 (0.11 to 
1.22)
0.56 (0.17 to 
1.87)
No RA 
medication
394 68 (17.3) 1.60 (0.93 to 
2.76)
1.49 (0.86 to 
2.57)
85 (21.6) 1.40 (0.89 to 
2.23)
1.35 (0.85 to 
2.14)
Patients categorised according to therapy registered within 1 year prior to pneumonia admission.
Each patient was assigned to one group using the hierarchy described in the text and shown in online supplementary figure 1.
*Adjusted for sex, age, level of comorbidity, alcoholism, and antibiotic use before admission.
†Prescriptions for prednisolone 0–3 months prior to admission.
csDMARDs, conventional synthetic disease- modifying antirheumatic drugs.
Interaction between prednisolone and disease activity in 
patients with Ra
In estimating the prognostic effect of prednisolone strat-
ified by disease activity before pneumonia admission, we 
found 90- day crude HRs of 0.30 (95% CI 0.04 to 2.59) 
in patients with low CRP levels and 1.45 (95% CI 1.02 to 
2.05) in patients with elevated CRP levels prior to admis-
sion. When adjusting for sex, age, level of comorbidity, 
alcoholism and antibiotic use prior to admission, the 
30- day and 90- day HRs for mortality were 0.24 (95% CI 
0.03 to 2.10) and 1.32 (95% CI 0.91 to 2.22), respectively. 
The all- cause 30- day and 90- day mortality rates and the 
crude and adjusted HRs for 30- day and 90- day mortality 
were evaluated for the following four groups (with the 
first group as reference): (1) patients with no prescrip-
tion for prednisolone and low CRP levels, (2) patients 
with no prescription for prednisolone and elevated CRP 
levels, (3) patients with a prescription for prednisolone 
and low CRP levels and (4) patients with a prescription 
for prednisolone and elevated CRP levels (table 5). In 
patients with high disease activity, 90- day mortality was 
18.1% in non- prednisolone users and 25.7% in predni-
solone users. Compared with non- users of prednisolone 
with low RA activity, the adjusted HRs were 2.35 (95% 
CI 0.94 to 5.87) for patients with high RA activity and no 
prednisolone use prior to admission and 3.09 (95% CI 
1.25 to 7.65) for patients with high RA activity and pred-
nisolone use prior to admission.
dIsCussIOn
In this population- based study including more than 
50 000 patients hospitalised due to pneumonia, we found 
that active arthritis negatively influenced the outcome. 
Since flares of RA are often treated with prednisolone, 
it may be difficult to separate the effect of prednisolone 
from the effect of disease activity. In this study, we were 
able to compare pneumonia outcomes in patients with 
RA with and without prednisolone treatment within 
strata of patients with similar disease activity. Predniso-
lone treatment in patients with low disease activity was 
not associated with increased mortality, in contrast to 
patients with high disease activity who had increased 
mortality irrespective of prednisolone use. Patients with 
RA did not, on average, have higher 30- day or 90- day 
mortality than individuals without RA.
To our knowledge, our study is the first to investigate 
the influence of RA disease activity per se on the prognosis 
of severe infection. Our results indicate that concerning 
severe infections, clinical focus should be on the risk of 
uncontrolled disease activity rather than just on potential 
dangers of RA medication. If patients with RA with high 
disease activity are treated more aggressively to obtain 
remission/low- grade disease activity, this might lead to 
better outcomes for patients with RA with infections. 
Our data were unable to answer whether or not immu-
nosuppressive RA medications should be stopped in case 
of severe infection, since we did not have information 
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Table 5 Results of all- cause mortality in patients with rheumatoid arthritis following hospitalisation for pneumonia according 
to disease activity and treatment with prednisolone
No prednisolone
+low CRP
No prednisolone
+high CRP
Prednisolone 
treatment
+low CRP
Prednisolone 
treatment
+high CRP
No of patients (N) 64 310 42 288
All- cause mortality at 30 days, 
n (%)
4 (6.3) 41 (13.2) 1 (2.4) 43 (14.9)
Crude HR for 30- day mortality 1 (ref) 2.20 (0.78 to 6.13) 0.38 (0.04 to 3.37) 2.48 (0.89 to 6.91)
Adjusted HR for 30- day mortality 1 (ref) 2.08 (0.74 to 5.81) 0.36 (0.04 to 3.23) 2.11 (0.76 to 5.88)
All- cause mortality at 90 days, 
n (%)
5 (7.8) 56 (18.1) 1 (2.4) 74 (25.7)
Crude HR for 90- day mortality 1 (ref) 2.46 (0.98 to 6.14) 0.29 (0.03 to 2.55) 3.57 (1.44 to 8.83)
Adjusted HR for 90- day mortality 1 (ref) 2.35 (0.94 to 5.87) 0.29 (0.03 to 2.52) 3.09 (1.25 to 7.65)
Data are presented as HRs with 95% CIs for all- cause mortality.
Treatment with prednisolone 0–3 months prior to admission. CRP levels were measured 30–90 days prior to pneumonia admission with a 
value of 8 mg/L used as a division between low and high CRP levels.
Adjusted for sex, age, level of comorbidity, alcoholism and antibiotic use before admission.
CRP, C reactive protein.
on in- hospital treatment following admission, including 
information on in- hospital treatment with prednisolone
The strengths of this study include the size and accu-
racy of the data sources used. We had complete follow- up 
data from detailed, high- quality registries, which allowed 
for extensive control of confounders. However, we chose 
our potential confounders because we wanted to examine 
the association between RA and pneumonia outcome. 
We may not have included all needed confounders to 
examine the association between other chronic diseases 
and pneumonia outcome thus our estimates may be 
affected by residual confounding. Recall and selection 
bias were limited because of the prospectively recorded 
population- based data. However, the identification of 
patients with RA through the DNPR might have excluded 
patients with RA with mild disease (ie, patients who were 
not treated at a hospital clinic or admitted for another 
illness without concomitant registration of RA in the 
DNPR). Since the treatment guidelines for RA treatment 
advocate early treatment with csDMARDs, which are 
usually administered at hospital clinics, these patients 
most likely account for only a limited number of patients, 
who would not have influenced the results significantly.
Patients with RA who attend regular follow- up are 
informed of the importance of contacting a physician in 
case of infection. This could lead to an earlier diagnosis of 
pneumonia and possibly to a higher likelihood of being 
hospitalised, which may underestimate the impact of RA 
on pneumonia mortality. On that same note, patients 
with RA taking biologics may be hospitalised earlier and/
or more frequently than patients being managed with 
other RA treatments when infection is suspected and 
thus are not as seriously affected, which may lead to an 
underestimation of mortality.
CRP measurements within 30–90 days prior to admis-
sion were available for 58% of the patients with RA. It 
is possible that patients with higher RA disease activity 
were more likely to have laboratory test done, but since 
most patients have laboratory test done at regular inter-
vals—and we omitted measurements 0–30 days prior to 
admission to avoid any influence from the subsequent 
infection the number of laboratory test is to be expected.
By using MTX as a reference drug, we may have over-
estimated the influence of comparative drugs because 
the risks associated with comorbidities that prohibit the 
use of MTX or with MTX failure, rather than risk associ-
ated with other RA medications, was measured. However, 
we adjusted for comorbidities, including previous alco-
holism related diagnoses.
Of 1220 patients with RA, 394 did not receive RA 
therapy 0–12 months prior to admission. But 123 of them 
had previously (more than 1 year prior to the admission) 
been prescribed csDMARDS and 310 of them had been 
on NSAIDS. It is likely that this group of patient are 
in remission or have low disease activity and therefore 
not on RA medication. Of the 1220 patients, 46 (3.8%) 
were on biologics. In the yearly rapport from DANBIO 
concerning 2005, 1390 patient with RA were treated with 
biologics. The estimated point prevalence in the southern 
part of Denmark in 2004 has been estimated to 0.30 (95% 
CI 0.17 to 0.50) while the cumulative prevalence was 0.75 
(95% CI 0.52 to 0.97),23 which means that 25.000–37.500 
persons had RA at that time. Thus, the rates of RA treated 
with biologics match the number in our data.
We were able to adjust for a broad range of comorbid-
ities using the Charlson Comorbidity Index, but not for 
lifestyle factors, such as smoking and body mass index. 
Smoking is linked to the development and severity of 
RA.24 Bello et al found an increased risk of 30- day mortality 
following hospitalisation for pneumonia among smokers 
even after taking tobacco- related comorbidity, age and 
other comorbid conditions into account.25 This could 
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lead to an overestimation of the relative mortality when 
comparing patients with RA to non- RA. However, it also 
possible that the prevalence of smoking was high among 
the non- RA patients in this study, since smoking is an 
important risk factor for pneumonia.26
In conclusion, patients with RA do not have a higher 
mortality following hospitalisation than patients without 
RA. However, high RA disease activity prior to admis-
sion predicts increased mortality following hospitalised 
pneumonia in patients with or without prednisolone 
use. This suggests that high RA disease activity per se is 
an important prognostic factor in patients with RA with 
pneumonia and should be controlled. Reassuringly, treat-
ment with biologics and csDMARDs, either as a mono-
therapy or in combination, did not predict increased 
pneumonia mortality.
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